Improving quality of life - The new target for transplantation

Transplantation

Volumn 72, Issue 12 SUPPL., 2001, Pages

  Keown, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; GRAFT SURVIVAL; HEALTH CARE SYSTEM; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEUROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL TECHNIQUE;

EID: 0035677782     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Recent advances in the diagnosis and management of infection in the organ transplant recipient
2. Long-term complications in renal transplantation
3. Causes of late renal allograft loss: Chronic allograft dysfunction, death, and other factors
4. Assessment of quality-of-life outcomes
5. Quality-of-life assessments and chronic liver disease
6. Quality of life after pancreas transplantation: A review
7. The Sickness Impact Profile: Development and final revision of a health status measure
8. The MOS 36-item short-form health survey (SF-36), I: Conceptual framework and item selection
9. Measuring health status: A new tool for clinicians and epidemiologists
10. Disease-specific questionnaire for patients with a renal transplant
11. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin
12. Development of the kidney disease quality of life (KDQOL) instrument
13. An introduction to utility measurement in health care
14. Preference for endpoint measures in clinical trials: Results of structured workshops
15. Dialysis and renal transplantation
16. Changes in patients' quality of life after renal transplantation
17. A qualitative study comparing adjustment and acceptance of illness in adults on renal replacement therapy
18. Kidney transplantation improves quality of life
19. Quality of life of renal transplant recipients
20. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant
21. Differences in quality of life across renal replacement therapies: A meta-analytic comparison
22. Comparison before and after transplantation of pancreas-kidney with loss of pancreas - A prospective controlled quality of life study
23. Evaluation of the quality of life of patients with insulin-dependent diabetes mellitus before and after organ transplantation with the SF 36 Health Survey
24. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation
25. Quality of life and cognitive function of liver transplant patients: A prospective study
26. Impact of liver transplantation on health-related quality of life
27. Children and families can achieve normal psychological adjustment and a good quality of life following pediatric liver transplantation: A long-term study
28. Cardiac transplantation
29. Clinical outcomes, quality of life, and cost outcomes after cardiac transplantation
30. Heart transplantation in patients over 54 years of age: Mortality, morbidity and quality of life
31. A study of the quality of life and cost-utility of renal transplantation
32. Long-term survival in renal transplant recipients with graft function
33. Improved graft survival after renal transplantation in the United States, 1988 to 1996
34. The patient's appraisal of side effects: The blind spot in quality-of-life assessments in transplant recipients
35. Symptom experience associated with maintenance immunosuppression after heart transplantation: Patients' appraisal of side effects
36. Impact of symptom frequency and symptom distress on self-reported quality of life in heart transplant recipients
37. Life satisfaction following heart transplantation
38. Quality of life in end-stage renal disease patients after successful kidney transplantation: Development of the ESRD Symptom Checklist-Transplantation Module
39. Newer immunosuppressive drugs: A review
40. A review of interleukin-2 receptor antagonists in solid organ transplantation
41. The interleukin-2 inhibitors and their role in low-toxicity regimens
42. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis
43. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation
44. Reduction of acute renal allograft rejection by daclizumab
45. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
46. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus
47. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
48. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
49. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
50. Absorption profiling of cyclosporine microemulsion (Neoral) during the first two weeks after renal transplantation
51. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
52. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
53. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
54. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial
55. Mycophenolate mofetil in cadaveric renal transplantation
56. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
57. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
58. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
59. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary/mismatched renal allografts
60. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
61. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
62. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience
63. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation
64. The economics of immunosuppression in renal transplantation: A review of recent literature
65. Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation
66. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation